BioSpace News Archive

T2 Biosystems, Inc. today announced that it received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) on May 21, 2024 informing the Company that it has regained compliance with the market value of listed securities (“MVLS”) requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (the “Rule”).

Eagle Pharmaceuticals, Inc. announced that it received a notice on May 20, 2024, from the Listing Qualifications Department of The Nasdaq Stock Market LLC advising the Company that it has initiated a process to delist the Company’s securities from Nasdaq because the Company had not filed its Form 10-Q for the quarter ended September 30, 2023 and its Form 10-K for the year ended December 31, 2023 by May 13, 2024.

Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, proudly announces the successful completion of its acquisition of Volpara Health Technologies, a global leader in medical software for breast cancer screening.

Theradaptive, Inc., a regenerative medicine company developing targeted therapeutics, announced it has been awarded funding from the Maryland Stem Cell Research Fund to support human clinical trials for its lead product, OsteoAdapt SP.

Today, COTA announced an extension of its research collaboration with the U.S. Food and Drug Administration’s (FDA) Oncology Center of Excellence.

GE HealthCare has topped a U.S. Food and Drug Administration list of artificial intelligence enabled medical devices for the third year in a row with 72 listed 510 clearances or authorizations to date in the United States.

GRI Bio, Inc. today announced the release of a Virtual Investor “What This Means” segment.

Matica Biotechnology (Matica Bio) announced today that it will participate in the world’s largest biotech exhibition, the BIO International Convention (BIO USA).

Allez Health Inc., formerly known as Zense-Life Inc., an emerging biosensor venture founded by proven experts in the continuous glucose monitoring space, announced a $60 million Series A+ financing.

Psychiatric disorders like schizophrenia, bipolar disorder and depression have a strong genetic signature. Through advanced transcriptome-wide association studies, researchers can identify unique gene expression profiles to identify new drug targets to treat these disorders.